（I am not a native English speaker, and I am using translation software.）
I am analyzing a highly atypical N=1 case of Treatment-Resistant Depression (TRD) with severe somatic neuropathic pain. I am trying to understand the receptor-level and blood-brain barrier (BBB) mechanics behind a complete failure of classical psychedelics in this specific pathology.
Case Profile:
Underlying Pathology:Chronic glutamate excitotoxicity suspected to be driven by Voltage-Gated Calcium Channel (VGCC) dysregulation (potentially autoimmune/microglial priming from severe Early Life Stress).
Current Maintenance:Requires massive doses of α2δ ligands (e.g., Pregabalin 2400mg/day or equivalent Mirogabalin) to suppress somatic pain and glutamate storms.
Suspected BBB Anomaly: Extreme P-glycoprotein (P-gp/ABCB1)
overexpression. (Evidence: Duloxetine blood serum levels were 3x the upper limit of normal, yet zero central CNS efficacy/side effects).
The Paradox (The Experiment): The subject was administered a massive dose of mescaline (San Pedro extract, well above the threshold for ego dissolution). The α2δ ligands were temporarily discontinued during the trial.
My Questions for the community:
> 1. P-gp Efflux: Is mescaline a strong enough substrate for P-gp that an overexpressed efflux pump could completely prevent it from reaching the 5-HT2A receptors in the PFC, allowing only trace amounts into the visual cortex?
2. Receptor Downregulation vs. Glutamate Noise: Could chronic, extreme glutamate toxicity physically destroy/downregulate 5-HT2A dendritic spines to the point where the psychedelic has no hardware to bind to? Or was the weak serotonergic signal simply drowned out by the deafening "noise" of the glutamate rebound storm?
3. Bypassing the BBB: In such a heavily fortified BBB model, would intranasal administration of an NMDA antagonist (like Esketamine/Spravato) theoretically bypass the P-gp pumps via the olfactory/trigeminal neural pathways to initiate mTOR-driven synaptogenesis?
Any insights into the molecular dynamics here would be highly appreciated.
I am analyzing a highly atypical N=1 case of Treatment-Resistant Depression (TRD) with severe somatic neuropathic pain. I am trying to understand the receptor-level and blood-brain barrier (BBB) mechanics behind a complete failure of classical psychedelics in this specific pathology.
Case Profile:
Underlying Pathology:Chronic glutamate excitotoxicity suspected to be driven by Voltage-Gated Calcium Channel (VGCC) dysregulation (potentially autoimmune/microglial priming from severe Early Life Stress).
Current Maintenance:Requires massive doses of α2δ ligands (e.g., Pregabalin 2400mg/day or equivalent Mirogabalin) to suppress somatic pain and glutamate storms.
Suspected BBB Anomaly: Extreme P-glycoprotein (P-gp/ABCB1)
overexpression. (Evidence: Duloxetine blood serum levels were 3x the upper limit of normal, yet zero central CNS efficacy/side effects).
The Paradox (The Experiment): The subject was administered a massive dose of mescaline (San Pedro extract, well above the threshold for ego dissolution). The α2δ ligands were temporarily discontinued during the trial.
My Questions for the community:
> 1. P-gp Efflux: Is mescaline a strong enough substrate for P-gp that an overexpressed efflux pump could completely prevent it from reaching the 5-HT2A receptors in the PFC, allowing only trace amounts into the visual cortex?
2. Receptor Downregulation vs. Glutamate Noise: Could chronic, extreme glutamate toxicity physically destroy/downregulate 5-HT2A dendritic spines to the point where the psychedelic has no hardware to bind to? Or was the weak serotonergic signal simply drowned out by the deafening "noise" of the glutamate rebound storm?
3. Bypassing the BBB: In such a heavily fortified BBB model, would intranasal administration of an NMDA antagonist (like Esketamine/Spravato) theoretically bypass the P-gp pumps via the olfactory/trigeminal neural pathways to initiate mTOR-driven synaptogenesis?
Any insights into the molecular dynamics here would be highly appreciated.
